Biocon (BIOCON.NS) Stock Price
Biocon Price
Revenue has compounded at 16.9% per year over the past 19 years to 152.62 B INR. Earnings per share have grown at 9.5% per year over the last 19 years. Biocon's net margin stands at 6.6%, down from 10.4% several years earlier. Biocon currently offers a dividend yield of about 0.12%. The payout ratio is around 6% of earnings. Analysts set a median price target of 450.84 INR, implying 12.6% above the current price. Of 18 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 18% above its 52-week low.
Biocon stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biocon over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biocon stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biocon's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biocon Price |
|---|---|
| 9/2/2026 | 400.30 INR |
| 9/1/2026 | 401.05 INR |
| 8/31/2026 | 402.60 INR |
| 8/28/2026 | 411.10 INR |
| 8/27/2026 | 415.80 INR |
| 8/26/2026 | 417.50 INR |
| 8/25/2026 | 417.20 INR |
| 8/24/2026 | 409.40 INR |
| 8/21/2026 | 415.55 INR |
| 8/20/2026 | 412.50 INR |
| 8/19/2026 | 414.15 INR |
| 8/18/2026 | 417.50 INR |
| 8/17/2026 | 412.00 INR |
| 8/14/2026 | 417.00 INR |
| 8/13/2026 | 420.00 INR |
| 8/12/2026 | 428.10 INR |
| 8/10/2026 | 426.10 INR |
| 8/7/2026 | 426.35 INR |
| 8/6/2026 | 436.60 INR |
| 8/5/2026 | 425.20 INR |
| 8/4/2026 | 424.95 INR |
| 7/31/2026 | 425.70 INR |
| 7/30/2026 | 424.50 INR |
| 7/28/2026 | 435.25 INR |
| 7/27/2026 | 436.25 INR |
| 7/24/2026 | 433.65 INR |
| 7/23/2026 | 433.50 INR |
| 7/22/2026 | 437.95 INR |
| 7/21/2026 | 440.30 INR |
| 7/20/2026 | 436.50 INR |
Biocon Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocon Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB INR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB INR |
| EBITB INR |
| EBIT MARGIN% |
| NET INCOMEB INR |
| NET INCOME GROWTH% |
| DIVIDENDDIV.INR |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESB |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.77 | 30.90 | 33.81 | 39.22 | 41.30 | 55.14 | 63.01 | 71.43 | 81.84 | 111.74 | 147.56 | 152.62 | 169.94 | 194.38 | 222.63 | 243.15 |
| 15.77 | 7.39 | 9.42 | 15.99 | 5.31 | 33.53 | 14.26 | 13.37 | 14.57 | 36.54 | 32.05 | 3.43 | 11.35 | 14.39 | 14.53 | 9.22 |
| 50.62 | 51.98 | 53.49 | 56.42 | 53.72 | 59.30 | 62.50 | 62.88 | 60.83 | 61.07 | 62.83 | 65.94 | 65.94 | 65.94 | 65.94 | 65.94 |
| 14.57 | 16.06 | 18.09 | 22.13 | 22.18 | 32.70 | 39.38 | 44.91 | 49.79 | 68.24 | 92.71 | 100.64 | 112.06 | 128.18 | 146.81 | 160.34 |
| 5.21 | 5.08 | 5.29 | 7.05 | 4.44 | 9.46 | 10.52 | 9.45 | 11.86 | 16.26 | 17.83 | 14.79 | 20.00 | 22.88 | 26.20 | 28.62 |
| 18.10 | 16.44 | 15.63 | 17.97 | 10.75 | 17.15 | 16.70 | 13.23 | 14.49 | 14.55 | 12.09 | 9.69 | 11.77 | 11.77 | 11.77 | 11.77 |
| 4.14 | 4.97 | 5.50 | 6.12 | 3.72 | 9.05 | 7.48 | 7.41 | 6.48 | 4.63 | 10.23 | 10.13 | 6.52 | 11.35 | 18.36 | 23.10 |
| -18.69 | 20.20 | 10.66 | 11.21 | -39.16 | 143.10 | -17.35 | -1.03 | -12.44 | -28.64 | 120.99 | -0.90 | -35.70 | 74.14 | 61.80 | 25.84 |
| 5.00 | 5.00 | 5.00 | 1.00 | 1.00 | 0.50 | 0.50 | – | 0.50 | 1.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | – |
| – | – | – | -80.00 | – | -50.00 | – | – | – | 200.00 | -66.67 | – | – | – | – | – |
| 1.19 | 1.20 | 1.18 | 1.19 | 1.19 | 1.19 | 1.19 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biocon generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biocon retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biocon's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biocon has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biocon's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biocon stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocon Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocon business model & stock analysis
Biocon Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biocon historical P/E ratio, EBIT multiple, and P/S ratio
Biocon annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biocon shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocon stock splits
Biocon Dividend History
21 years of dividend payments
Biocon dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocon dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Biocon forecasts and price targets in September 2026
Analyst Price Targets 2026Biocon Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/21/2024 | 3.54INR | - | 44.47 BINR | - | 2024 Q4 |
| 2/12/2024 | 2.82INR | - | 38.47 BINR | - | 2024 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Biocon stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Biocon shareholder structure
| % | Name |
|---|---|
29.92484% | |
14.64872% | |
6.99366% | |
5.67933% | |
3.84948% | |
3.42418% |
Biocon Beneficial Ownership Filings (SEC 13D/G)
Biocon Executives and Management Board
20 members · avg. age 59 · 20 % women
Mr. Siddharth Mittal (47)
Chief Executive Officer, Managing Director, Executive Director · since 2014
73.71 M INR
Management
Mr. Mukesh Kamath
Interim Chief Financial Officer
Mr. Shreehas Tambe (51)
Chief Executive Officer, Managing Director - Biocon Biologics Limited
Mr. Arun Gupta
Chief Operating Officer
Mr. Manoj Pananchukunnath
Chief Scientific Officer · since 2024
Mr. Rajesh Shanoy
Compliance Officer, Company Secretary
Mr. Amit Kaptain
Head - Commercial API
Board of Directors
Ms. Kiran Mazumdar-Shaw (72)
Executive Chairperson of the Board · since 2020
Mr. Bobby Parikh (61)
Non-Executive Independent Director
Mr. Nicholas Haggar (60)
Non-Executive Independent Director
Ms. Naina Kidwai (68)
Lead Non-Executive Independent Director
Prof. Ravi Mazumdar (70)
Non-Executive Non-Independent Director
Mr. Atul Dhawan
Additional Non-Executive Independent Director
Frequently asked questions about Biocon
Analysts currently set an average price target of 439.62 INR for the Biocon stock (median: 450.84 INR), implying +9.4 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Biocon stock: 12 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Biocon to generate revenue of 169.94 B INR and earnings per share of 5.44 INR.
Converted at the current exchange rate, the Biocon share trades at 3.65 EUR (400.30 INR).
No history available for Biocon.
The expected revenue of Biocon is 169.94 B INR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biocon is 6.52 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biocon is currently 73.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biocon stock.
The price-to-sales ratio (P/S) of Biocon is currently 2.82. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biocon stock.
The Eulerpool Quality Score for Biocon is 7/10.
The ISIN of Biocon is INE376G01013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Biocon is BIOCON.NS. The ticker symbol is used to trade Biocon shares on the stock exchange.
Over the past 12 months, Biocon paid a dividend of 0.50 INR . This corresponds to a dividend yield of about 0.12 %. For the coming 12 months, Biocon is expected to pay a dividend of 0.50 INR.
The current dividend yield of Biocon is 0.12 %.
Biocon pays a dividend, distributed in the months of , , , .
Biocon paid dividends every year for the past 4 years.
For the upcoming 12 months, dividends amounting to 0.50 INR are expected. This corresponds to a dividend yield of 0.12 %.
Biocon is assigned to the 'Health' sector.
To receive the latest dividend of Biocon from amounting to 0.5 INR, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Biocon distributed 1.5 INR as dividends.
The dividends of Biocon are distributed in INR.
Biocon stock
Biocon Peer Group
Biocon Ticker
Biocon FIGI
All fundamentals and in-depth analysis of Biocon
Our stock analysis for Biocon stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocon. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.